GW Pharmaceuticals Plc, which has a cannabinoid product for multiple sclerosis in registration in Europe, has entered an exclusive strategic alliance with a professor at the University of Buckingham to investigate cannabinoids for metabolic disease.
GW Pharmaceuticals Plc, which has a cannabinoid product for multiple sclerosis in registration in Europe, has entered an exclusive strategic alliance with a professor at the University of Buckingham to investigate cannabinoids for metabolic disease.